{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:45Z","timestamp":1791928845592,"version":"4.3.4"},"reference-count":160,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2023,6,30]]},"DOI":"10.1167\/iovs.64.7.39","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T10:31:00Z","timestamp":1688121060000},"page":"39","source":"Crossref","is-referenced-by-count":130,"title":["Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions"],"prefix":"10.1167","volume":"64","author":[{"given":"Selina","family":"Drag","sequence":"first","affiliation":[{"name":"Ocugen, Inc., Malvern, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farokh","family":"Dotiwala","sequence":"additional","affiliation":[{"name":"Ocugen, Inc., Malvern, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Ocugen, Inc., Malvern, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"795010","DOI":"10.3389\/fgene.2021.795010","article-title":"Gene-based therapeutics for acquired retinal disease: opportunities and progress","volume":"12","author":"Tan","year":"2021","journal-title":"Front Genet"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1073\/pnas.1913179117","article-title":"Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases","volume":"117","author":"Hanany","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2176\/nmc.ra.2020-0049","article-title":"Historic overview of genetic engineering technologies for human gene therapy","volume":"60","author":"Tamura","year":"2020","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"key":"bib5","first-page":"2535","article-title":"Adenovirus vector-mediated in vivo gene transfer into adult murine retina","volume":"35","author":"Bennett","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib6","first-page":"2543","article-title":"In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector","volume":"35","author":"Li","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/hmg\/5.5.591","article-title":"Gene transfer into the mouse retina mediated by an adeno-associated viral vector","volume":"5","author":"Ali","year":"1996","journal-title":"Hum Mol Genet"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"10319","DOI":"10.1073\/pnas.94.19.10319","article-title":"Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector","volume":"94","author":"Miyoshi","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","article-title":"What is CRISPR\/Cas9?","volume":"101","author":"Redman","year":"2016","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/biom12020269","article-title":"Advances in ophthalmic optogenetics: approaches and applications","volume":"12","author":"Prosseda","year":"2022","journal-title":"Biomolecules"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/14712598.2020.1740676","article-title":"Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development","volume":"20","author":"Ciulla","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/virology.2019.6.issue-1","article-title":"Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): where are we, and how did we get here?","volume":"6","author":"Keeler","year":"2019","journal-title":"Annu Rev Virol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","article-title":"Seeing the light after 25 years of retinal gene therapy","volume":"24","author":"Trapani","year":"2018","journal-title":"Trends Mol Med"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"100353","DOI":"10.1016\/j.cobme.2021.100353","article-title":"AAV manufacturing for clinical use: insights on current challenges from the upstream process perspective","volume":"20","author":"Dobrowsky","year":"2021","journal-title":"Current Opinion in Biomedical Engineering"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/14712598.2020.1693541","article-title":"Current challenges in biotherapeutic particles manufacturing","volume":"20","author":"Moleirinho","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.xphs.2021.03.024","article-title":"Manufacturing challenges and rational formulation development for AAV viral vectors","volume":"110","author":"Srivastava","year":"2021","journal-title":"J Pharm Sci"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"846782","DOI":"10.3389\/fmed.2022.846782","article-title":"Subretinal therapy: technological solutions to surgical and immunological challenges","volume":"9","author":"Ladha","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol Ther"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","article-title":"Systemic and local immune responses to intraocular AAV vector administration in non-human primates","volume":"24","author":"Ail","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.immuni.2022.04.012","article-title":"Immunological defense of CNS barriers against infections","volume":"55","author":"Ampie","year":"2022","journal-title":"Immunity"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/hum.2019.144","article-title":"Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: relative contribution of genome and capsid","volume":"31","author":"Timmers","year":"2020","journal-title":"Hum Gene Ther"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.trsl.2017.06.012","article-title":"Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates","volume":"188","author":"Matet","year":"2017","journal-title":"Transl Res"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/pharmaceutics14091973","article-title":"Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy","volume":"14","author":"Ren","year":"2022","journal-title":"Pharmaceutics"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"12818","DOI":"10.3390\/ijms222312818","article-title":"Risk mitigation of immunogenicity: a key to personalized retinal gene therapy","volume":"22","author":"Varin","year":"2021","journal-title":"Int J Mol Sci"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.addr.2006.07.023","article-title":"Non-viral ocular gene therapy: potential ocular therapeutic avenues","volume":"58","author":"Bloquel","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nm0696-649","article-title":"Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy","volume":"2","author":"Bennett","year":"1996","journal-title":"Nat Med"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/bjophthalmol-2016-309975","article-title":"Leber congenital amaurosis\/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions","volume":"101","author":"Kumaran","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"101115","DOI":"10.1016\/j.preteyeres.2022.101115","article-title":"Therapy with voretigene neparvovec. How to measure success?","volume":"92","author":"Stingl","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-319-95046-4","article-title":"Autosomal dominant retinitis pigmentosa","volume":"1085","author":"Tsang","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/fcp.v35.1","article-title":"Progress on ocular siRNA gene-silencing therapy and drug delivery systems","volume":"35","author":"Jiang","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci China Life Sci"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2119\/molmed.2010.00070","article-title":"Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization","volume":"16","author":"Salminen","year":"2010","journal-title":"Mol Med"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"a023754","DOI":"10.1101\/cshperspect.a023754","article-title":"Genome-editing technologies: principles and applications","volume":"8","author":"Gaj","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"775330","DOI":"10.3389\/fgeed.2021.775330","article-title":"Prime editing for inherited retinal diseases","volume":"3","author":"da Costa","year":"2021","journal-title":"Front Genome Ed"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat Med"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/hum.2020.231","article-title":"Genome-editing strategies for treating human retinal degenerations","volume":"32","author":"Quinn","year":"2021","journal-title":"Hum Gene Ther"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00439-008-0560-2","article-title":"Identifying modifier genes of monogenic disease: strategies and difficulties","volume":"124","author":"Genin","year":"2008","journal-title":"Hum Genet"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1749-6632.2010.05879.x","article-title":"Modifier genes in Mendelian disorders: the example of cystic fibrosis","volume":"1214","author":"Cutting","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"e1002644","DOI":"10.1371\/journal.pgen.1002644","article-title":"Modifier genes and the plasticity of genetic networks in mice","volume":"8","author":"Hamilton","year":"2012","journal-title":"PLoS Genet"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35056009","article-title":"Modifer genes in mice and humans","volume":"2","author":"Nadeau","year":"2001","journal-title":"Nat Rev"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12915-020-00845-w","article-title":"Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy","volume":"18","author":"Walsh","year":"2020","journal-title":"BMC Biol"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"e87942","DOI":"10.1371\/journal.pone.0087942","article-title":"Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease","volume":"9","author":"Cruz","year":"2014","journal-title":"PLoS One"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41434-020-0134-z","article-title":"Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa","volume":"28","author":"Li","year":"2020","journal-title":"Gene Ther"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00335-008-9092-2","article-title":"Mapping of genetic modifiers of Nr2e3 rd7\/rd7 that suppress retinal degeneration and restore blue cone cells to normal quantity","volume":"19","author":"Haider","year":"2008","journal-title":"Mamm Genome"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","article-title":"Gene therapy: advances, challenges and perspectives","volume":"15","author":"Goncalves","year":"2017","journal-title":"Einstein (Sao Paulo)"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1089\/hum.2019.159","article-title":"Helper-dependent adenovirus transduces the human and rat retina but elicits an inflammatory reaction when delivered subretinally in rats","volume":"30","author":"Han","year":"2019","journal-title":"Hum Gene Ther"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/vision.2017.3.issue-1","article-title":"Vectors and gene delivery to the retina","volume":"3","author":"Planul","year":"2017","journal-title":"Annu Rev Vis Sci"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1128\/jvi.70.6.4173-4178.1996","article-title":"Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy","volume":"70","author":"Gorziglia","year":"1996","journal-title":"J Virol"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1073\/pnas.91.13.6196","article-title":"Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver","volume":"91","author":"Engelhardt","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1128\/JVI.72.2.926-933.1998","article-title":"Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted","volume":"72","author":"Amalfitano","year":"1998","journal-title":"J Virol"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/cgt.2009.17","article-title":"Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity","volume":"16","author":"Osada","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"8934","DOI":"10.1128\/jvi.70.12.8934-8943.1996","article-title":"Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy","volume":"70","author":"Gao","year":"1996","journal-title":"J Virol"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2217\/fvl.11.6","article-title":"Implications of the innate immune response to adenovirus and adenoviral vectors","volume":"6","author":"Gregory","year":"2011","journal-title":"Future Virology"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"eaat9321","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Sci Transl Med"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","article-title":"Pharmaceutical development of AAV-based gene therapy products for the eye","volume":"36","author":"Rodrigues","year":"2018","journal-title":"Pharm Res"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","article-title":"Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis","volume":"26","author":"Le Meur","year":"2018","journal-title":"Mol Ther"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"e13392","DOI":"10.15252\/emmm.202013392","article-title":"Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders","volume":"13","author":"Pavlou","year":"2021","journal-title":"EMBO Mol Med"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"588234","DOI":"10.3389\/fnins.2020.588234","article-title":"Mutation-independent therapies for retinal diseases: focus on gene-based approaches","volume":"14","author":"Carrella","year":"2020","journal-title":"Front Neurosci"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1039\/C3SC52951G","article-title":"Inteins: nature's gift to protein chemists","volume":"5","author":"Shah","year":"2014","journal-title":"Chem Sci"},{"key":"bib69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","article-title":"Dual-AAV delivering split prime editor system for in vivo genome editing","volume":"30","author":"Zhi","year":"2022","journal-title":"Mol Ther"},{"key":"bib70","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.omtm.2021.10.004","article-title":"Inclusion of a degron reduces levelsof undesired inteins after AAV-mediated proteintrans-splicing in the retina","volume":"23","author":"Tornabene","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib71","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1089\/hum.2018.156","article-title":"An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4(-\/-) mice","volume":"30","author":"McClements","year":"2019","journal-title":"Hum Gene Ther"},{"key":"bib72","article-title":"Some genes are too large to fit into AAV vectors. UCB, Novartis back $57M idea to deliver them in parts instead","author":"Tong","year":"2022","journal-title":"Endpoints News"},{"key":"bib73","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/pharmaceutics14081605","article-title":"Lentiviral vectors for ocular gene therapy","volume":"14","author":"Arsenijevic","year":"2022","journal-title":"Pharmaceutics"},{"key":"bib74","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/156652311798192888","article-title":"Anti-inflammatory gene therapy for cardiovascular disease","volume":"11","author":"Matoba","year":"2011","journal-title":"Curr Gene Ther"},{"key":"bib75","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.msec.2017.04.068","article-title":"Non-viral strategies for ocular gene delivery","volume":"77","author":"Oliveira","year":"2017","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"bib76","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"bib77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/pharmtox.2017.57.issue-1","article-title":"Aptamers as therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"bib78","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp Mol Med"},{"key":"bib79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J Control Release"},{"key":"bib80","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.actbio.2020.11.003","article-title":"Gene transfection achieved by utilizing antibacterial calcium phosphate nanoparticles for enhanced regenerative therapy","volume":"119","author":"Xiang","year":"2021","journal-title":"Acta Biomater"},{"key":"bib81","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.actbio.2011.09.013","article-title":"A new tool for the transfection of corneal endothelial cells: calcium phosphate nanoparticles","volume":"8","author":"Hu","year":"2012","journal-title":"Acta Biomater"},{"key":"bib82","doi-asserted-by":"publisher","first-page":"e5290","DOI":"10.1371\/journal.pone.0005290","article-title":"A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles","volume":"4","author":"Cai","year":"2009","journal-title":"PLoS One"},{"key":"bib83","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pone.0000038","article-title":"Efficient non-viral ocular gene transfer with compacted DNA nanoparticles","volume":"1","author":"Farjo","year":"2006","journal-title":"PLoS One"},{"key":"bib84","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1096\/fsb2.v24.4","article-title":"Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa","volume":"24","author":"Cai","year":"2010","journal-title":"FASEB J"},{"key":"bib85","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1096\/fsb2.v29.6","article-title":"Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype","volume":"29","author":"Han","year":"2015","journal-title":"FASEB J"},{"key":"bib86","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1172\/JCI64833","article-title":"DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice","volume":"122","author":"Han","year":"2012","journal-title":"J Clin Invest"},{"key":"bib87","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.phrs.2016.07.042","article-title":"Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat","volume":"111","author":"Amadio","year":"2016","journal-title":"Pharmacol Res"},{"key":"bib88","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/pharmaceutics14010090","article-title":"Lipid nanoparticles for the posterior eye segment","volume":"14","author":"Bonilla","year":"2021","journal-title":"Pharmaceutics"},{"key":"bib89","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1167\/iovs.10-5891","article-title":"A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib90","doi-asserted-by":"publisher","first-page":"e0241006","DOI":"10.1371\/journal.pone.0241006","article-title":"The effects of PEGylation on LNP based mRNA delivery to the eye","volume":"15","author":"Ryals","year":"2020","journal-title":"PLoS One"},{"key":"bib91","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3390\/biom11081135","article-title":"The ocular gene delivery landscape","volume":"11","author":"Sahu","year":"2021","journal-title":"Biomolecules"},{"key":"bib92","doi-asserted-by":"publisher","first-page":"eabg2661","DOI":"10.1126\/sciadv.abg2661","article-title":"High-purity production and precise editing of DNA base editing ribonucleoproteins","volume":"7","author":"Jang","year":"2021","journal-title":"Sci Adv"},{"key":"bib93","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat Biotechnol"},{"key":"bib94","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/0110-5558.76435","article-title":"Niosome: a future of targeted drug delivery systems","volume":"1","author":"Kazi","year":"2010","journal-title":"J Adv Pharm Technol Res"},{"key":"bib95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.015","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): fabrication, characterization, pharmaceutical and cosmetic applications","volume":"144","author":"Chen","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"bib96","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/pharmaceutics12030198","article-title":"Niosome-based approach for in situ gene delivery to retina and brain cortex as immune-privileged tissues","volume":"12","author":"Al Qtaish","year":"2020","journal-title":"Pharmaceutics"},{"key":"bib97","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/nano10061191","article-title":"Niosomal drug delivery systems for ocular disease-recent advances and future prospects","volume":"10","author":"Durak","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"bib98","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2019.05.010","article-title":"Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes","volume":"304","author":"Mashal","year":"2019","journal-title":"J Control Release"},{"key":"bib99","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2017.03.386","article-title":"Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60","volume":"254","author":"Mashal","year":"2017","journal-title":"J Control Release"},{"key":"bib100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2013.11.004","article-title":"A novel cationic niosome formulation for gene delivery to the retina","volume":"174","author":"Puras","year":"2014","journal-title":"J Control Release"},{"key":"bib101","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ijpharm.2018.07.035","article-title":"Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration","volume":"550","author":"Villate-Beitia","year":"2018","journal-title":"Int J Pharm"},{"key":"bib102","doi-asserted-by":"publisher","first-page":"13665","DOI":"10.1021\/acsami.2c02182","article-title":"Nanodiamond integration into niosomes as an emerging and efficient gene therapy nanoplatform for central nervous system diseases","volume":"14","author":"Al Qtaish","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"bib103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2016.07.013","article-title":"Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants","volume":"170","author":"Birch","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"bib104","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","article-title":"Neuroprotective strategies for retinal disease","volume":"65","author":"Pardue","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"bib105","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41419-018-1041-8","article-title":"Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor\/tropomyosin-related kinase receptor-B signaling","volume":"9","author":"Osborne","year":"2018","journal-title":"Cell Death Dis"},{"key":"bib106","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1167\/iovs.08-3013","article-title":"Effect of CNTF on retinal ganglion cell survival in experimental glaucoma","volume":"50","author":"Pease","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib107","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omtn.2019.01.012","article-title":"Suppression of choroidal neovascularization by AAV-based dual-acting antiangiogenic gene therapy","volume":"16","author":"Askou","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"bib108","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4155\/fmc.11.176","article-title":"miRNAs as potential therapeutic targets for age-related macular degeneration","volume":"4","author":"Wang","year":"2012","journal-title":"Future Med Chem"},{"key":"bib109","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40291-016-0234-z","article-title":"An eye on age-related macular degeneration: the role of microRNAs in disease pathology","volume":"21","author":"Berber","year":"2017","journal-title":"Mol Diagn Ther"},{"key":"bib110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.11.4.3","article-title":"Tropism of AAV vectors in photoreceptor-like cells of human iPSC-derived retinal organoids","volume":"11","author":"McClements","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"bib111","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41593-019-0431-2","article-title":"Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans","volume":"22","author":"J\u00fcttner","year":"2019","journal-title":"Nat Neurosci"},{"key":"bib112","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4939-3271-9","article-title":"Controlling AAV tropism in the nervous system with natural and engineered capsids","volume":"1382","author":"Castle","year":"2016","journal-title":"Methods Mol Biol"},{"key":"bib113","doi-asserted-by":"publisher","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"bib114","doi-asserted-by":"publisher","first-page":"11372","DOI":"10.1128\/JVI.01327-07","article-title":"Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors","volume":"81","author":"Allocca","year":"2007","journal-title":"J Virol"},{"key":"bib115","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1089\/hum.2012.125","article-title":"The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina","volume":"23","author":"Boye","year":"2012","journal-title":"Hum Gene Ther"},{"key":"bib116","doi-asserted-by":"publisher","first-page":"e53463","DOI":"10.1371\/journal.pone.0053463","article-title":"AAV9 targets cone photoreceptors in the nonhuman primate retina","volume":"8","author":"Vandenberghe","year":"2013","journal-title":"PLoS One"},{"key":"bib117","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/tvst.11.3.13","article-title":"The learning curve of murine subretinal injection among clinically trained ophthalmic surgeons","volume":"11","author":"Huang","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"bib118","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1111\/bph.v174.23","article-title":"Principles of pharmacology in the eye","volume":"174","author":"Awwad","year":"2017","journal-title":"Br J Pharmacol"},{"key":"bib119","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"key":"bib120","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/jop.2019.0034","article-title":"Ophthalmic drug delivery using iontophoresis: recent clinical applications","volume":"36","author":"Perez","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib121","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular drug delivery: present innovations and future challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"bib122","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.clae.2021.101487","article-title":"Pharmaceutical-loaded contact lenses as an ocular drug delivery system: a review of critical lens characterization methodologies with reference to ISO standards","volume":"44","author":"Nguyen","year":"2021","journal-title":"Cont Lens Anterior Eye"},{"key":"bib123","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/02713683.2020.1826979","article-title":"Anterior migration of triamcinolone acetonide after posterior subtenon injection for macular edema predisposes to intraocular pressure elevation","volume":"46","author":"Yang","year":"2021","journal-title":"Curr Eye Res"},{"key":"bib124","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/11206721221108253","article-title":"Subtenon triamcinolone injection to treat serous choroidal detachment after glaucoma surgery: a case series","volume":"33","author":"Nilforushan","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"bib125","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin Drug Deliv"},{"key":"bib126","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"key":"bib127","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000479157","article-title":"Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases","volume":"58","author":"Peng","year":"2017","journal-title":"Ophthalmic Res"},{"key":"bib128","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.ymthe.2006.03.005","article-title":"Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection","volume":"13","author":"Jacobson","year":"2006","journal-title":"Mol Ther"},{"key":"bib129","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"key":"bib131","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/pharmaceutics13070967","article-title":"Drug delivery via the suprachoroidal space for the treatment of retinal diseases","volume":"13","author":"Naftali Ben Haim","year":"2021","journal-title":"Pharmaceutics"},{"key":"bib132","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib133","doi-asserted-by":"publisher","first-page":"100915","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"bib134","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.omtm.2020.05.014","article-title":"Ocular tolerability and immune response to corneal intrastromal AAV-IDUA gene therapy in New Zealand white rabbits","volume":"18","author":"Song","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib135","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/humc.2018.168","article-title":"Toxicology and pharmacology of an AAV vector expressing codon-optimized RPGR in RPGR-deficient Rd9 mice","volume":"29","author":"Song","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"bib136","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/hum.2019.297","article-title":"Toxicity and efficacy evaluation of an adeno-associated virus vector expressing codon-optimized RPGR delivered by subretinal injection in a canine model of X-linked retinitis pigmentosa","volume":"31","author":"Dufour","year":"2020","journal-title":"Hum Gene Ther"},{"key":"bib137","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1089\/hum.2018.144","article-title":"Dosage thresholds and influence of transgene cassette in adeno-associated virus-related toxicity","volume":"29","author":"Khabou","year":"2018","journal-title":"Human Gene Therapy"},{"key":"bib138","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib139","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/tvst.8.2.14","article-title":"Relationship between neutralizing antibodies against adeno-associated virus in the vitreous and serum: effects on retinal gene therapy","volume":"8","author":"Lee","year":"2019","journal-title":"Transl Vis Sci Technol"},{"key":"bib140","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"J Innate Immun"},{"key":"bib141","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"bib142","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","article-title":"Pre-existing antibody: biotherapeutic modality-based review","volume":"18","author":"Gorovits","year":"2016","journal-title":"AAPS J"},{"key":"bib143","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/jphp.12810","article-title":"Immunogenicity assessment during the development of protein therapeutics","volume":"70","author":"Rosenberg","year":"2018","journal-title":"J Pharm Pharmacol"},{"key":"bib144","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/antib7020019","article-title":"Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity","volume":"7","author":"Pratt","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"bib145","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.csbj.2020.12.024","article-title":"Deimmunization of protein therapeutics - Recent advances in experimental and computational epitope prediction and deletion","volume":"19","author":"Zinsli","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"bib146","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/anie.v58.8","article-title":"Proactively reducing anti-drug antibodies via immunomodulatory bioconjugation","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"key":"bib147","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12974-015-0431-4","article-title":"Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration","volume":"12","author":"Scholz","year":"2015","journal-title":"J Neuroinflammation"},{"key":"bib148","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"bib149","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"key":"bib150","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3390\/jcm9051556","article-title":"Preoperative, intraoperative and postoperative corticosteroid use as an adjunctive treatment for rhegmatogenous retinal detachment","volume":"9","author":"Bonfiglio","year":"2020","journal-title":"J Clin Med"},{"key":"bib151","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/IAE.0b013e3181e3789c","article-title":"Influence of systemic steroids on subretinal fluid after scleral buckle surgery for macula-off retinal detachment","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"bib152","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/a-1777-5033","article-title":"Importance of nonhuman primates as a model system for gene therapy development in ophthalmology","volume":"239","author":"Wozar","year":"2022","journal-title":"Klin Monbl Augenheilkd"},{"key":"bib153","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1517\/21678707.2015.1069179","article-title":"Obstacles and future of gene therapy for hemophilia","volume":"3","author":"Arruda","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"bib154","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/pharmaceutics14091931","article-title":"Ocular drug delivery: advancements and innovations","volume":"14","author":"Tian","year":"2022","journal-title":"Pharmaceutics"},{"key":"bib155","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.2147\/OPTH.S313719","article-title":"The impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective","volume":"15","author":"Gong","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"bib156","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1021\/jp803077n","article-title":"Enhanced transfection efficiency of multicomponent lipoplexes in the regime of optimal membrane charge density","volume":"112","author":"Caracciolo","year":"2008","journal-title":"J Phys Chem B"},{"key":"bib157","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1039\/C4BM00303A","article-title":"The transfection efficiency of calix[4]arene-based lipids: the role of the alkyl chain length","volume":"3","author":"Mochizuki","year":"2015","journal-title":"Biomater Sci"},{"key":"bib158","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2144\/000112404","article-title":"In vivo gene delivery in the retina using polyethylenimine","volume":"42","author":"Liao","year":"2007","journal-title":"Biotechniques"},{"key":"bib159","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1039\/C4NR04284K","article-title":"Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells","volume":"7","author":"Mastorakos","year":"2015","journal-title":"Nanoscale"},{"key":"bib160","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1248\/bpb.b12-00728","article-title":"Ocular gene delivery systems using ternary complexes of plasmid DNA, polyethylenimine, and anionic polymers","volume":"36","author":"Kurosaki","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"bib41","article-title":"Small interfering RNA (siRNA) based therapy","author":"Padda","year":"2022"},{"key":"bib130"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2791262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:44Z","timestamp":1791927104000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2791262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":160,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.64.7.39","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}